Email updates

Keep up to date with the latest news and content from BMC Psychiatry and BioMed Central.

Open Access Open Badges Correction

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Paul D Carey1*, Bavanisha Vythilingum1, Soraya Seedat1, Jacqueline E Muller1, Michael van Ameringen2 and Dan J Stein1

Author Affiliations

1 MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa

2 Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada

For all author emails, please log on.

BMC Psychiatry 2005, 5:44  doi:10.1186/1471-244X-5-44

Published: 30 November 2005

First paragraph (this article has no abstract)

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].